Abstract: The present invention is concerned with the use of indolocarbazole imides of the general formula (I): ##STR1## for the preparation of pharmaceutical compositions for the treatment and/or prevention of cancer, virus diseases (for example HIV infections), heart and blood vessel diseases (for example high blood pressure, thromboses, heart rhythm disturbances and atheroscleroses), bronchopulmonary diseases, degenerative diseases of the central nervous system (for example Alzheimer's disease), inflammatoryl diseases (for example rheumatism and arthritis), diseases of the immune system (for example allergies), as well as psoriasis and for use as immune suppressives; as well as new compounds of general formula (I).

Abstract: The present invention is concerned with the use of indolocarbazole imides of the general formula (I): ##STR1## for the preparation of pharmaceutical compositions for the treatment and/or prevention of cancer, virus diseases (for example HIV infections), heart and blood vessel diseases (for example high blood pressure, thromboses, heart rhythm disturbances and atheroscleroses), bronchopulmonary diseases, degenerative diseases of the central nervous system (for example Alzheimer's disease), inflammatory diseases (for example rheumatism and arthritis), diseases of the immune system (for example allergies), as well as psoriasis and for use as immune suppressives; as well as new compounds of general formula (I).

Abstract: Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

Abstract: Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.

Abstract: The present invention provides indolocarbazole derivatives of the formula ##STR1## as well as the regioisomeric mixtures thereof, pharmacologically acceptable salts thereof, processes for the preparation thereof, and pharmaceutical compositions containing them for the treatment and/or prophylaxis of heart and blood vessel diseases, such as thromboses, arterioscleroses, hypertonias, of bronchopulmonary diseases, inflammatory processes, allergies, cancers and degenerative damage of the central nervous system, and for the treatment of viral diseases.

Abstract: New indolocarbazoles of formula: ##STR1## or a pharmaceutically acceptable salt thereof, processes for their preparation, compositions containing, and methods for using the composition for the inhibition of protein kinases, such as protein kinase C, for the prevention and/or treatment of heart and blood vessel diseases such as thromboses, arterioscleroses, hypertension, or for inflammatory processes, allergies, cancers, viral diseases, and certain degenerative damages of the central nervous system are disclosed.

Abstract: The present invention provides 9,10,11,12-tetrahydro-9,12-epoxy-1H-diindolo [1,2,3-fg: 3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione and 9,10,11,12-tetrahydro-2-(tetrahydro-5-methoxy-2-furanyl) -9,12-epoxy-1H-diindolo[1,2,3-fg: 3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione process for the preparation thereof, pharmaceutical compositions containing the compounds, and use of the compounds in heart and blood vessel diseases such as thromboses, arterioscleroses, hypertension and inflammatory diseases, allergies, cancer and certain degenerative damage of the central nervous system, as well as diseases of the immune system.

Abstract: The present invention concerns the fumaric acid salts of 1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl) 1,6-naphthyridine-3-carboxylic acid [2-(N-methyl-N-phenylmethylamino)ethyl]ester, processes for preparing them, and pharmaceutical compositions containing them. Methods of using the compounds for treating high blood pressure and diseases of heart and blood vessels.

Abstract: The present invention provides a process for the separation of the naphthyridine derivatives (.+-.)-1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-n aphthyridine-3-carboxylic acid ethyl ester and (.+-.)-1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-n aphthyridine-3-carboxylic acid [2-(N-methyl-N-phenylmethylamino)ethyl] ester into the optical antipodes by use of the (.+-.)-1,4-dihydro-5-isopropoxy-2-methyl-4-(2-trifluoromethylphenyl)-1,6-n aphthyridine-3-carboxylic acid benzyl ester and optically-active O,O'-dibenzoyltartaric acid. Said optical antipodes are calcium antagonists useful in the treatment of blood vessel diseases.

Abstract: The invention concerns new pyrrolocarbazole derivatives of formula ##STR1## processes for their preparation, as well as medicaments containing these for the inhibition of protein kinases, such as protein kinase C, and thus for the prevention and/or treatment of heart and blood vessel diseases, such as thromboses, arterioscleroses, hypertension, of inflammatory processes, allergies, cancers, and certain degenerative damages of the central nervous system as well as for the treatment of viral diseases.

Abstract: 4-Alkoxy-pyrido[2,3-d]pyrimidine derivatives are described as well as processes for their preparation.For reason of their vasospasmolytic effects these compounds are mainly indicated for the treatment of cerebral, cardiac, and peripheral vascular diseases such as myocardiac ischemia, cerebral infarction, pulmonary thromboses, as well as in cases of arterioschlerosis and other stenotic disorders. They are therefore valuable agents for combating cardiovascular mortality.

Abstract: The present invention describes 1,6-naphthyridine derivatives of the general formula: ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromatic or heteroaromatic ring, R.sup.2 is a straight-chained or branched alkyl radical containing up to four carbon atoms or a benzyl radical, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radicals or an alkoxycarbonyl radical containing up to four carbon atoms, R.sup.4 is a straight-chained or branched alkyl radical containing up to four carbons and R.sup.5 is a carboxyl group or a straight-chained, branched or cyclic alkoxycarbonyl radical which contains up to 17 carbon atoms and optionally also contains an oxygen, sulphur or nitrogen atom; as well as the pharmacologically acceptable salts thereof, which are useful for treating diseases of the blood vessels.

Abstract: The present invention provides a unique series of pyrido[4,3-b][1,6]naphthyridine derivatives. The compounds are calcium antagonists and are useful for blood vessel diseases. This invention also covers processes for preparing the compounds, pharmaceutical compositions containing them, and methods for using them.

Abstract: The present invention describes 1,6-naphthyridine derivatives of the general formula: ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromtic or heteroaromatic ring, R.sup.2 is a straight-chained or branched alkyl radical containing up to four carbon atoms or a benzyl radical, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radical or an alkoxycarbonyl radical containing up to four carbon atoms, R.sup.4 is a straight-chained or branched alkyl radical containing up to four carbons and R.sup.5 is a carbonyl group or a straight-chained, branched or cyclic alkoxycarbonyl radical which contains up to 17 carbon atoms and optionally also contains an oxygen, sulphur or nitrogen atom; as well as the pharamacologically acceptable salts thereof, which are useful for treating diseases of the blood vessels.

Abstract: New 1,6-naphthyridinone derivatives of the formula I ##STR1## are herein described wherein R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic ring;R.sup.2 is hydrogen, a straight-chained or branched alkyl, alkoxyalkyl, or a substituted or unsubstituted aminoalkyl group with up to ten carbon atoms;R.sup.3 is hydrogen, a straight-chained or branched alkyl group, or an alkoxycarbonyl radical with up to four carbon atoms;R.sup.4 is hydrogen, or a morpholinoethyl group;R.sup.5 is a straight-chained or branched alkyl group with up to four carbon atoms, or an amino group; andR.sup.6 is a carboxyl group, or an alkyl- or alkyloxyalkyl carbonyl radical, containing up to 12 carbon atoms and optionally interrupted by an oxygen, sulphur, or nitrogen atom;as well as optionally the pharmacologically acceptable salts thereof; processes for the preparation of these derivatives and their use in the control of vascular diseases.

Abstract: The invention concerns new 5-alkoxy-pyrido[4,3-d]pyrimidine derivatives and pharmacologically acceptable salts thereof, as well as a chemically novel process for their preparation. The new compounds are used in the control of cerebral, cardiac or peripheral vascular diseases or of stenotic symptoms.

Abstract: The invention concerns new 5-oxo-pyrido[4,3-d]pyrimidine derivatives and the pharmacologically acceptable salts thereof, as well as a chemically novel process for the preparation of the new compounds and their use in the control of cerebral, cardiac, or peripheral vascular diseases or of stenotic symptoms.

Abstract: 4-Oxo-pyrido[2,3-d]pyrimidine derivatives are herein described as well as processes for their preparation.These compounds possess valuable pharmacological properties. As calcium antagonists they exert vasospasmolytic, vasodilatory, and antihypertensive activities. Surprisingly some of the compounds also have the effect of increasing contractility. They are therefore particularly suited for the treatment of vascular diseases.